Amphion Innovations plc

 ("Amphion" or "the Company")

Order Dismissing DataTern Case

London and New York, 2 November 2017 - Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, announces that on 20 October 2017 the case brought by DataTern Inc. ("DataTern"), a wholly-owned subsidiary of Amphion, against MicroStrategy Inc. and certain of its customers was dismissed.

The reason for the case dismissal was the withdrawal of DataTern's legal counsel and the inability of DataTern to identify and appoint a successor counsel in the short time frame set by the Court.

It remains DataTern's considered opinion that the 502 and 402 patents are both valid and being infringed by a wide range of companies that are practicing this critical art. In order to pursue these claims though, DataTern needs to be able to fund the expenses in the programme and efforts to find a suitable funding source and successor legal counsel are continuing.

For further information please contact:

About Amphion Innovations plc

Amphion Innovations is a developer of medical, life science and technology businesses. We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in a small number of Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies.

On the web: www.amphionplc.com